Overview
Frank is a full time Professor of Biostatistics and Bioinformatics and Faculty Director for Biostatistics at Duke University Medical Center, Affiliate Professor of Biostatistics at Virginia Commonwealth University, and Strategic Consultant at Hunter Rockhold, Inc. His 40+-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he retired as Chief Safety Officer and Senior Vice President of Global Clinical Safety and Pharmacovigilance. He has held faculty appointments at six different universities. Dr. Rockhold served for 9 years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials and a past member of the PCORI Clinical Trials Advisory Panel. He is currently Chair of the Board of the Frontier Science and Technology Research Foundation and a technical advisor to EMA.
Dr. Rockhold has diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, benefit/risk, safety and pharmacovigilance and has been a leader in the scientific community in promoting data disclosure and transparency in clinical research. Frank is widely published in major scientific journals across a wide variety of research topics.
Frank holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from The Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. Frank is an Elected Fellow of both the American Statistical Association and the Society for Clinical Trials, a Fellow of the Royal Statistical Society, an Accredited Professional Statistician, PStat®, and a Chartered Statistician, CStat.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Methodologic Standards for Follow-Up Extension in Cardiovascular Trials: A Scientific Statement From the American Heart Association
Journal article Circulation · August 3, 2026 Extension follow-up trials are essential for understanding the long-term safety and efficacy of cardiovascular interventions. Whereas primary randomized trials primarily capture short ... Full text CiteLong-term safety of the Pfizer-BioNTech COVID-19 vaccine: Results from the HERO-together study.
Journal article Respir Med · June 2026 BACKGROUND: COVID-19 vaccines were initially authorized based on short-term data from Phase 3 clinical trials in a highly selected population. OBJECTIVES: This study assessed the long-term safety of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 and variati ... Full text Link to item CiteAdditive prognostic value of functional performance to coronary artery anatomy: the ISCHEMIA trial.
Journal article Eur Heart J Cardiovasc Imaging · April 30, 2026 AIMS: To assess whether baseline functional performance assessed by exercise treadmill stress testing (EST) has additive value to coronary computed tomography angiography (CCTA) for risk stratification among patients with chronic coronary disease (CCD) and ... Full text Link to item CiteRecent Grants
RECOVER Infrastructure Modification 11 (Yr 3)
ResearchInvestigator · Awarded by Research Triangle Institute International · 2022 - 2027Integrated Biostatistical Training for CVD Research
Inst. Training Prgm or CMEMentor · Awarded by North Carolina State University · 2022 - 2027Infrastructure for Musculoskeletal Pediatric Acute Care Clinical Trials (IMPACCT)
ResearchStatistical Investigator · Awarded by Ann & Robert H. Lurie Children's Hospital of Chicago · 2021 - 2027View All Grants